The in vitro activity of pazuoxacin as the active form of pazuoxacin mesilate, a new compound for intravenous administration, against recent clinical isolates of anaerobic bacteria

Abstract

The in vitro activity of pazuoxacin (PZFX) as the active form of pazuoxacin mesilate, a new compound for intravenous administration, was compared with that of tosuoxacin (TX), ciprooxacin CPFX), ceftazidime (CAZ), and imipenem (IPM) against anaerobic clinical strains isolated from 1994 to 1997.
Generally, PZFX was less active than IPM and TX, and equally active as CPFX and CAZ. In some species, PZFX was more active than CAZ.
PZFX displayed good antimicrobial activity against strains of Clostridium perfringens, Fusohacterium nucleatum, some species of Peptostreptococcus, Porphyromonas spp., some species of Prevotella, and Propionibacterium acnes. PZFX inhibited 90 % of the strains of those species at concentrations up to 1.56μg/ml. PZFX was less active against the Bacteroides fragilis group and Prevotella hivia, inhibiting 50 % of the strains of those species at the concentrations up to 6.25 μg/ml. No significant differences in susceptibility were observed between strains of the Bacteroides fragilis group isolated before 1991 and after 1994.